mend universal screening of lipid levels for young people aged 17 to 21 years and pharmacologic treatment with statins for those with low-density lipoprotein cholesterol (LDL-C) levels of at least 190 mg/dL (to convert to millimoles per liter, multiply by 0.0259) without other risk factors or at least 130 or 160 mg/dL if additional risk factors are present. In contrast, the 2013 American College of Cardiology and American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 3 recommends medication for individuals younger than 40 years only if their LDL-C level is at least 190 mg/dL. Because 17 to 21 years is a typical age for transition from pediatric to adult-centered care, these disparate approaches may lead to confusion in clinical practice.
Despite their different approaches, both guidelines have faced controversy because of concerns about overdiagnosis and overtreatment of individuals without known CVD. 4, 5 Previous analyses using the National Health and Nutrition Examination Surveys (NHANES) demonstrate that compared with prior guidelines, the 2011 pediatric guidelines and 2013 adult guidelines expand the number of Americans eligible for pharmacologic treatment of elevated LDL-C levels. 6, 7 However, no study has reported on discrepancies that arise when applying pediatric vs adult guidelines to adolescents transitioning to young adulthood. The aim of this study was to determine the proportion of young people aged 17 to 21 years who would meet criteria for pharmacologic treatment with statins under the 2 guidelines.
Methods
We performed a cross-sectional analysis of participants in the NHANES from January 1, 1999, through December 31, 2012, 8 who were 17 to 21 years of age (n = 6338); the analysis was performed from June through December 2014. NHANES is a program that assesses the health status of the United States using a nationally representative sampling strategy. Individuals 18 years or older provided written informed consent to collection of survey and biological data, and those younger than 18 years provided written assent along with parental written informed consent. 8 The analysis was deemed exempt by the institutional review board of the Tufts Health Sciences Campus. We excluded participants who were pregnant (1.8%) or who reported taking medication to lower lipid levels at the time of the examination (2.8%). NHANES investigators calculated LDL-C levels from measured total cholesterol, triglyceride, and high-density lipoprotein cholesterol (HDL-C) levels using the Friedewald equation. 3 We included the 2.2% of participants with nonfasting cholesterol levels because a nonfasting LDL-C level carries a prognosis similar to that of a fasting LDL-C level. 9 We included data regarding family history of early atherosclerotic CVD (ASCVD), defined as a first-or a second-degree relative with a heart attack or angina before age 50 years. This question was asked of participants 20 years or older starting in 2005. We included those answers and imputed answers for the remaining population (see below). We included data on moderate-level risk factors (stage I hypertension, class I obesity, and HDL-C level <40 mg/dL) and high-level risk factors (stage II hypertension, class II or III obesity, self-reported history of diabetes mellitus, and self-reported use of tobacco cigarettes on at least 20 days in the past month (individuals aged 17-19 years) or on some or most days (individuals aged 20-21 years). Personal history of ASCVD was not considered because the estimated prevalence was believed to be implausibly high and likely related to inaccurate self-report. Data on rare high-risk conditions, such as heart transplant and Kawasaki disease, for which treatment at lower LDL-C levels is recommended in the pediatric guidelines, 2 were not available. Based on a Markov chain Monte Carlo method, 10 which assumes multivariate normality, we used multiple imputation (PROC MI, SAS, version 9.4; SAS Institute Inc) to estimate missing values for all other variables included in the pediatric and adult guidelines, including LDL-C levels, which were collected on only 2652 of 6338 participants (41.8%). Ten data sets were imputed. 10 We applied treatment algorithms from the 2011 integrated pediatric guidelines and the 2013 adult guidelines to the sample of 6338 participants (Figure) . We used software to specify the subgroup variable (PROC SURVEYFREQ, SAS, version 9.4) and the subgroup of interest (SURVEYMEANS, SAS, version 9.4) on each imputed data set to incorporate NHANES sampling weights for the complex sample design and to account for clusters and strata. We then used multiple imputation (PROC MIANALYZE; SAS, version 9.4) to combine results performed on the 10 imputed data sets. To extrapolate the results to a population of 20.4 million noninstitutionalized young people aged 17 to 21 years living in the United States, we applied proportions to the Current Population Survey in accordance with the NHANES analytic guidelines 11 and rounded to the nearest hundred. We performed 3 sensitivity analyses. First, we analyzed data for male and female individuals separately. Second, we
At a Glance
• Physicians who care for adolescents transitioning to adulthood often face incongruent recommendations from pediatric and adult guidelines.
• Of the 6338 young people aged 17-21 years in NHANES, 2.5% would qualify for statin treatment under the pediatric guidelines compared with 0.4% under the adult guidelines.
• Participants who met pediatric criteria had lower mean LDL-C levels but higher proportions of other cardiovascular risk factors, including hypertension, smoking, and obesity. • These differences translate into statin treatment for more than 400 000 additional adolescents and young adults under the pediatric than the adult guidelines.
• Given the current uncertain state of knowledge and conflicting lipid treatment guidelines for youth aged 17-21 years, clinicians and patients should engage in shared decision making around potential benefit, harms, and patient preferences for treatment.
stead of self-report to classify participants as smokers. Third, to examine the effect of prior adult guidelines, we applied the third report of the National Cholesterol Education Program Guidelines in Adults (Adult Treatment Panel III [ATP III]), 13 which recommended pharmacologic treatment for individuals with 2 or more risk factors and LDL-C levels of at least 160 mg/dL (or ≥130 mg/dL if the 10-year risk for ASCVD is 10%-20%). For determining statin therapy based on LDL-C level under the ATP III, we assumed that all individuals aged 17 to 21 years had a less than 10% chance of an ASCVD event within 10 years owing to their youth because the ATP III risk calculator extends only to 30 years of age. All analyses were performed using commercially available software (SAS, version 9.4).
Results
Demographic and clinical characteristics of the noninstitutionalized US population of young people aged 17 to 21 years represented by the NHANES population and the subset eligible for statin therapy by the pediatric and adult guidelines are shown in Table 1 and 17 to 21 years would be treated if the pediatric and adult guidelines, respectively, were fully applied. Participants who met pediatric criteria for treatment had lower mean total cholesterol and LDL-C levels but higher triglyceride levels than those meeting adult criteria ( Table 2 ). The presence of these risk factors would increase the proportion of male individuals aged 17 to 21 years eligible for therapy 7.3-fold (from 0.4% with the adult guidelines to 2.9% with the pediatric guidelines) and increase the proportion of female individuals aged 17 to 21 years eligible for treatment by 5.3-fold (from 0.4% to 2.1%).
Compared with the current adult guidelines, application of the ATP III guideline 13 increased the proportion of participants qualifying for treatment from 0.4% to 0.7% (95% CI, 0.3%-1.1%). Classifying smoking status based on cotinine levels slightly increased the proportion meeting the pediatric guidelines for statin therapy from 2.5% to 3.1% (95% CI, 2.3%-3.8%).
Discussion
Physicians who care for adolescents transitioning to adulthood often face incongruent recommendations from pediatric and adult guidelines. In this study, we focused on deciding whether to prescribe medication to lower lipid levels to people in this age group. Application of the pediatric guidelines resulted in recommendations for statin treatment for more young people overall and for young people with lower LDL-C levels but a higher prevalence of other CVD risk factors compared with the adult guidelines. These differences are not surprising given the current criteria considered in the 2 guidelines (Figure) . 2, 3 However, direct application of the 2 guidelines in clinical practice has the potential to create confusion for patients and physicians. For example, if a pediatric cardiologist prescribes a statin for a 20-year-old obese male with an LDL-C level of 170 mg/dL who smokes cigarettes and has a family history of early ASCVD, should the patient continue taking the statin when he transitions to a physician who treats adults? Given that the underlying risk does not change when these pa- Abbreviations: ACC-AHA, American College of Cardiology and American Heart Association; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NHANES, National Health and Nutrition Examination Surveys; NHLBI, National Heart, Lung, and Blood Institute; SBP, systolic blood pressure. Copyright 2015 American Medical Association. All rights reserved.
tients change physicians, starting the statin therapy in adolescence but stopping it in adulthood is counterintuitive. Treatment decisions regarding individuals such as those with low short-term but high lifetime risks for ASCVD are hampered by the lack of randomized clinical trials in young adults.
14 Such trials would require extensive follow-up to answer questions about the effect of statin therapy on the risk for CVD events. In their absence, policy makers and physicians often rely on data from genetic 15 and epidemiologic 16 studies that suggest that the lifetime risk for ASCVD in individuals with elevated LDL-C levels in conjunction with other CVD risk factors early in life is high. The 2011 pediatric guidelines are based on this type of extrapolated evidence for areas in which trial evidence was unavailable. 2 In contrast, the 2013 adult guidelines were created using evidence from randomized clinical trials only, although they advocate for the physician's judgment in areas where the evidence base is insufficient. 3 In the future, policy makers should consider creating guidelines that can be applied more seamlessly across the life course. Our study has important limitations. The analysis was based on measurements collected at a single point. In contrast, guidelines for the diagnosis and treatment of hyperlipidemia call for multiple measurements over time and for consideration of treatment after a trial of lifestyle changes. Second, very few participants had LDL-C levels of 190 mg/dL or greater; thus, estimates for treatment under the adult guidelines may be unstable owing to small sample sizes. Third, we chose not to consider individuals eligible based on self-report of ASCVD, an important eligibility criteria in both guidelines, because of concerns that these reports were implausible in this age group and hence inaccurate. Finally, family history of ASCVD was self-reported, not verified through clinical records, and only asked of participants 20 years or older. Although we attempted to address the high rate of missing data for a family history of ASCVD with multiple imputation, we still might have underestimated the number of young people who would qualify for statin treatment under the pediatric guidelines for individuals with LDL-C levels of 160 to 189 mg/dL and a family history of early ASCVD.
Conclusions
Our analysis suggests that for young people aged 17 to 21 years in the United States who have elevated LDL-C levels, direct application of the pediatric guidelines would result in statin treatment for more than 400 000 additional young people than the adult guidelines, a 6-fold difference. The actual number treated is likely to be much lower owing to less than universal screening in this age group, 17 challenges with adherence to medication regimens, 18 and physician or patient disagreement with the recommendations. Given the current uncertain state of knowledge and conflicting guidelines for treatment of lipid levels among youth aged 17 to 21 years, physicians and patients should engage in shared decision making around the potential benefits, harms, and patient preferences for treatment. 19 The 2013 American College of Cardiology and American Heart Association guidelines recommend shared decision making with patients for whom data are inadequate, including young people with a high lifetime risk for ASCVD. 3 Patients and cli- 
